阻断EP2和EP4可以防止人体单细胞骨髓原体衍生抑制细胞中瘤诱导的抑制特征
Jorge Cuenca-Escalona1, Beatriz Subtil1, Alba Garcia-Perez1
1Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, Netherlands.
Frontiers in immunology
|February 12, 2024
概括
瘤衍生的前列腺素E2 (PGE2) 通过EP2/4受体促进免疫抑制的髓质衍生抑制细胞 (MDSCs). 阻止这些受体可以防止MDSC诱导的免疫抑制,从而成为潜在的癌症治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 分子信号传输的方法
背景情况:
- 瘤创造了一个抑制性的微环境,促进免疫逃避和进展.
- 骨髓原抑制细胞 (MDSC) 是这种免疫抑制的关键参与者,与癌症患者的不良结果有关.
- 瘤衍生的前列腺素E2 (PGE2) 驱动MDSC分化和前瘤功能,通过髓状细胞中的EP2和EP4受体发出信号.
研究的目的:
- 研究EP2和EP4受体在暴露于瘤衍生PGE2时人类单细胞MDSC (M-MDSC) 中的作用.
- 确定阻断EP2/4信号是否可以防止M-MDSCs中抑制特征的诱导.
- 评估针对M-MDSC中PGE2-EP2/4轴的治疗潜力,以获得抗瘤免疫力.
主要方法:
- 使用了人类单细胞MDSCs (M-MDSCs) 的体外模型.
- 评估了PGE2对M-MDSC表型和功能的影响,包括T和NK细胞抑制.
- 与PGE2暴露相结合,使用了EP2/4受体阻塞.
- 在3D共同培养系统中评估了EP2/4封锁与结直肠癌患者衍生器官.
主要成果:
- 通过EP2和EP4受体传递PGE2信号显著增强了M-MDSCs的前瘤表型和功能.
- EP2/4信号增强了M-MDSC介导的T和NK细胞反应的抑制.
- 对EP2和EP4受体的联合阻断有效地阻止了暴露于PGE2.2的M-MDSCs中抑制特征的发展.
- EP2/4封锁也减弱了M-MDSCs的抑制表型在一个相关的3D共同培养模型.
结论:
- 通过EP2和EP4受体传递瘤衍生的PGE2信号,在诱导人类M-MDSC的免疫抑制功能方面发挥着关键作用.
- 针对PGE2-EP2/4轴是一个有希望的治疗策略,以缓解免疫抑制.
- 调节这种途径可以促进有效的抗瘤免疫的发展.
更多相关视频
14:15Preparation of Myeloid Derived Suppressor Cells MDSC from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting AutoMACS
Published on: June 18, 2012
26.3K
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
7.5K
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
